caps, and subjected to three freeze-thaw cycles by submerging in liquid nitrogen for 10 minutes and then completely thawing at 37C in water bath. Alternatively tubes can be chilled with dry ice for at least 30 minutes or at -80C for at least 1 hour per cycle before being completely thawed at 37C in water bath. Tubes were centrifuged at 6,000 g for 3 minutes with careful removal of supernatants and replenished with 1 ml 1% P/S/A/G solution between each freeze-thaw cycle and then vortexed to ensure even distribution of contents before starting the next cycle. After three cycles, erythrocyte lysis was performed twice by adding 1 ml erythrolysis buffer (ELB) to resuspend contents, incubating for 20-30 minutes at room temperature, and centrifuging at 6,000 g for 3 minutes. Samples were then subjected to two more freeze-thaw cycles as described above with 1 ml 1% P/S/A/G solution.
Samples were subsequently incubated with 250 U/ml deoxyribonuclease I (DNase I, 18047-019) and 25 U/ml ribonuclease A (RNase A, AM2274) at 37 °C for at least 1 hour (both from Life Technologies, Grand Island, NY, USA). Treatment with DNase I and RNase A was repeated after centrifugation at 6,000 g for 3 minutes and careful removal of the supernatant. After 2 rounds of DNA/RNA lysis, samples were washed three times with sterile 0.9% normal saline (Baxter Healthcare, Deerfield, IL, USA) and frozen at -80C for 1 hour. Samples were then washed with 0.9% normal saline, centrifuged at 6,000 g for 3 minutes with complete removal of supernatants, and subjected to lyophilization for 72 hours in original tubes in a sterilized chamber. Immediately after lyophilization, tubes were individually weighed to obtain the collective dry weights of lyophilized products. Lyophilized samples were finely crushed and ground for 15-20 minutes into fine powders in original tubes placed in a liquid nitrogen-cooled mini mortar (H37260-0100; Bel-Art Products, Wayne, NJ, USA). Lyophilized powders were stored at -80C for future use.
Preparation of cardiac ECM suspension and particle size measurement. Prior to applications, lyophilized cardiac ECM powders were weighed in a sterile container, resuspended in 0.9% normal saline, and sonicated in cool water for 15 min. Large particles were then removed by centrifugation at 300 × g. Cardiac ECM suspension was collected for immediate use or stored on dry ice for later use.
Cardiac ECM particle size was measured by Zetasizer Nano ZS90 (Malvern, Worcestershire, UK) and reported as the mean from 25 measurements. Results were then averaged from measurements of three independent samples. For in vivo administration, 0.5 mg of lyophilized zECM or mECM powders was resuspended in 30 l of 0.9% normal saline, sonicated and centrifuged as described above, and transported on dry ice to the operating room prior to the administration.
Myocardial infarction model. The induction of myocardial infarction (MI) and intramyocardial
injections have been performed as we previously reported (59, 60) . In brief, after the induction of anesthesia with 4% isoflurane gas, mice were intubated and inhalationally anesthetized with 2% isoflurane gas throughout the surgery. MI was microscopically induced by permanent ligation of the left anterior descending coronary artery (LAD). Mice were then randomly assigned to one of the four groups: hzECM, nzECM, mECM, or saline control. Five minutes after the induction of infarction, 30 l of zECM or mECM suspension was injected at three sites of the ischemic myocardium (center and two borders of the infarct; 10 l for each site). Control mice received injections of 30 l normal saline.
The investigator who induced MI and performed injections was blinded to the content of the injectant.
For ErbB2 inhibition in vivo, the ErbB2 inhibitor AG825 (sc-202045A; Santa Cruz Biotechnology, Dallas, TX, USA) was dissolved in dimethyl sulfoxide (DMSO) and intraperitoneally injected once at 5 mg/kg (20 to 25 l in volume) immediately after the cardiac ECM administration (40, 41) . Control mice received a sham injection or an intraperitoneal injection of 25 l DMSO alone.
Echocardiography. Echocardiographic studies were performed by a blinded investigator repeatedly before surgery and at 5 days, 2 weeks, and 6 weeks after surgery to assess the cardiac function, as we previously described (60, 61) . Briefly, mice were initially anesthetized with 2% isoflurane gas and subsequently maintained at 1-1.5% isoflurane gas throughout the echocardiographic study. Mice were then immobilized on a heated stage equipped with electrocardiography. Heart rate and respiratory rate were continuously monitored. The body temperature was maintained at 37°C.
Echocardiographic parameters were measured using a high-frequency linear probe (MS400, 30 MHz) connected to a high-resolution ultrasound imaging system (Vevo 2100; FUJIFILM VisualSonics, Toronto, Ontario, Canada). M-and B-mode frames were acquired at a frame rate of 235 Hz during each scan. At least three independent M-and B-mode scans (300 frames per scan) were recorded respectively for each animal at each time point. End-systolic dimension (ESD) and end-diastolic dimensions (EDD) were determined from short axis images of the left ventricle using M-mode scan.
Ten consecutive beats were measured from M-mode frames. Results were averaged. End-systolic area (ESA) and end-diastolic area (EDA) were measured from short-axis images of the LV using B-mode scan (minimum and maximum LV chamber area respectively). Functional parameters, including the LV fractional shortening (LVFS), LV fractional area change (LVFAC), and LV ejection fraction (LVEF), were determined as previously described (62, 63) . Mice that died, displayed morphological/behavioral abnormality, or were sacrificed for histological analysis nefore 6 weeks post-injection were not included in echocardiographic studies. 
fig. S9. c-kit + cells do not express mast cell marker tryptase. Dual immunofluorescent detection
of c-kit (CD117) and tryptase at 3 days post-MI showed no c-kit+ cells expressing tryptase in zECM and control groups (CD117 in red, tryptase in green, and DAPI in blue; scale bars = 100 μm). Supplemental Table S1_Danre Identified Protein Gene Name 
